



CONTACTS

Jordan Davis or **Daniel Lubin**

Radius Ventures

212/897-7778

jdavis@radiusventures.com or dlubin@radiusventures.com

Anthony Citrano

fama PR

617/758-4140

anthony@famapr.com

RADIUS VENTURE PARTNERS CLOSES \$73.5 MILLION SECOND FUND FOCUSED ON HEALTH AND LIFE SCIENCES BRINGING TOTAL CAPITAL UNDER MANAGEMENT TO NEARLY \$100M

Firm continues emphasis on early-stage investments across health and life sciences spectrum

NEW YORK, NY—February 18, 2003—Radius Ventures (www.RadiusVentures.com), a New York-based venture capital firm focused on health and life science investments, today announced the closing of its second fund, Radius Venture Partners II, L.P. at \$73.5 million bringing the firm's total capital under management to nearly \$100 million. Since its founding in 1997, Radius has been dedicated to a strategy of diversifying its investments across key sectors of the health and life science industry including medical devices, biotechnology, pharmaceutical, healthcare information technology and healthcare services. Radius Ventures' investments have included Amicas, BEI Medical Systems, Clinical Microsensors, Comprehensive Neurosciences, Nugen Technologies, and Zettacore.

“We were very pleased with the response of our limited partners, who see the opportunities created by this dynamic market and recognize our ability to identify, assess and add substantial value to our portfolio companies,” said Daniel Lubin, co-founder and managing partner of Radius Ventures. “Further, a large part of our success revolves around the disciplined approach we bring by integrating technical, operating-governance, and capital markets expertise into our investment process—this has been a key engine driving our organizational development.”

Radius Venture Partners II, L.P. Investing Methodology

The Fund will invest Radius Venture Partners II, L.P. primarily in early-stage companies in the medical device, biotechnology, pharmaceutical, healthcare information technology and healthcare services sectors. Radius' successful fund raising effort was bolstered by continued support from Bain Capital, which has had a close working relationship with Radius and is a strategic limited partner in the Radius Funds.

“In this challenging environment, Radius' success at closing this fund is a testament to the quality of the Radius team,” said Stephen Pagliuca, Managing Director at Bain Capital and a

member of Radius' Advisory Board. "Radius represents an important and influential player in the early-stage healthcare venture arena. We look forward to Radius' continued success."

Radius co-founder and managing partner Jordan Davis commented, "The health and life sciences industry is exploding with innovation and investment opportunities that can be obtained at exceptional valuations in today's investment climate. Our new fund is poised to benefit from this highly attractive environment, and we anticipate funding many exciting companies in Radius II. In fact, given today's valuation environment, we also intend to make selective investments in certain public and later-stage opportunities."

Radius' Industry-Leading Advisory Board

To support Radius' investment model, the firm has assembled an industry-leading advisory board that actively participates in Radius' investment process. Among Radius' advisors are: Scott T. Garrett, President, Beckman Coulter Clinical Diagnostics Division; William Hawkins, President of Medtronic's Vascular Division; Mehmet C. Oz, M.D., Vice-Chair of Surgery and Irving Professor of Cardiac Surgery at Columbia University and Director of Clinical Trials of New Surgical Technology; Brian Brille, Managing Director and Global Head of Healthcare Corporate and Investment Banking Group and Global Head of the Financial Sponsor Group at Banc of America Securities LLC; and Clayton Rose, former Head of Global Investment Banking division, JP Morgan & Co. and former Chairman, JP Morgan Securities, Inc.

"I am very impressed with the Radius team. These are high-energy, hard-working investors. Their hands-on approach to helping portfolio companies mature has earned them lasting respect from the managers that work with them," said Lawrence Mondschein, Managing Director of CRA Funding and Radius II limited partner. "The quality of their due diligence and nose for interesting opportunities makes them attractive partners to other quality venture groups active in the space. This credibility in the venture community is a source of deal flow and serves as a resource to assist portfolio companies."

About Radius Venture Partners

Radius Ventures is a New York City-based venture capital firm focused on early-stage opportunities within the health and life sciences industry. Founded in 1997, Radius manages two funds with total committed capital of approximately \$100 million. The firm invests up to \$5 million in each of its portfolio companies and pursues a highly active investment style, providing substantial resources and direction to company management. Radius seeks opportunities across a broad spectrum including biotechnology and pharmaceuticals, medical devices and products, health and life sciences enterprise and application software, and healthcare services. On a selective basis, Radius considers later-stage health and life sciences investments where the firm can uniquely apply its industry and capital markets experience. Radius is licensed as a Small Business Investment Company (SBIC). For more information, visit: www.RadiusVentures.com.